News

BURLINGAME, Calif.--(BUSINESS WIRE)--Aug. 30, 2016-- Pulse Biosciences, Inc., (NASDAQ: PLSE), a medical technology company developing a proprietary therapeutic treatment platform based on Nano-Pulse Electro-Signaling, today announced that it has appointed Holly Hartman, Ph.D., J.D., as its Vice President, Business Development and Corporate Strategy.

Dr. Hartman joins Pulse Biosciences after more than eight years in business development roles at Amgen where she helped to identify and evaluate strategic opportunities and partnerships for multiple therapeutic areas including oncology. Prior to Amgen, Dr. Hartman held various positions in investment banking working on life sciences transactions.

“We are excited to have someone with Dr. Hartman’s experience in immuno-oncology therapeutics and relationships in the biopharma community join our team,” said Darrin Uecker, CEO of Pulse Biosciences. "Pulse Biosciences is pioneering a medical device technology that has demonstrated a unique biologic effect and Dr. Hartman is uniquely qualified to work with key opinion leaders and potential partners as we explore the potential clinical applications for our technology.”

“I believe Pulse Bioscience’s platform technology provides an innovative approach to treating solid tumors and other indications,” said Dr. Hartman. “In particular, the pre-clinical data shows promise in the technology’s ability to target the tumor microenvironment while stimulating the host immune system capabilities. I believe our technology may offer a novel, toxicity-sparing approach to cancer care as a monotherapy and in combination with other modalities.”

Dr. Hartman earned her Ph.D. in comparative pathology with an emphasis in immunopathology, J.D. and B.A. in zoology all from the University of California, Davis.

About Pulse Biosciences

Pulse Biosciences is a medical technology company developing a therapeutic tissue treatment platform based on Nano-Pulse Electro-Signaling, a proprietary bioelectronics cell signaling technology. Published pre-clinical studies have shown that a single, brief exposure of Nano-Pulse Electro-Signaling to target tissue initiates a cascade of events within cells and in the surrounding microenvironment that results in apoptosis (cell death) and the priming of a durable adaptive immune response. Pulse Biosciences is pursuing a variety of applications for its technology that exploits the technology’s unique biologic effect in immuno-oncology, dermatology, aesthetics, and veterinary medicine. Clinical studies are being planned using the first commercial system designed to support a broad array of electrodes for use in superficial, minimally-invasive and open surgical procedures. More information is available at www.pulsebiosciences.com.

Forward Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the markets and market opportunity for our technology, the development of our business and technology, the anticipated benefits of our technology, our progress towards achieving clinical endpoints and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond our control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in our most recent filings with the Securities and Exchange Commission, including our most recent reports on Forms S-1, as amended, and 10-Q, and include those listed under the caption “Risk Factors.”

These forward-looking statements speak only as of the date hereof. Pulse Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160830006410/en/

Source: Pulse Biosciences, Inc.

Investors:
Pulse Biosciences, Inc.
Darrin Uecker, 650-376-0042
President and Chief Executive Officer
IR@pulsebiosciences.com
or
Media:
Sam Brown, Inc.
Hannah Hurdle, 818-456-4099
hannahhurdle@sambrown.com